Revisit Every OncLive On Air Episode From May 2026

In case you missed any, below is a recap of the episodes of OncLive On Air® that aired in May 2026. Check out our podcast page for a full episode lineup and to stay up to date with all the latest releases!

Metastatic Bladder Cancer 2026 UPDATE

In this video episode of Two Onc Docs, hosts Samantha A. Armstrong, MD, of Indiana University Health in Indianapolis, and Karine Tawagi, MD, of the University of Illinois in Chicago, highlight the evolution of metastatic urothelial carcinoma management strategies, the importance of understanding trial data, and the ins and outs of toxicity management.

“[Regarding] enfortumab vedotin-ejfv [Padcev] and pembrolizumab [Keytruda], we need to know about these drugs and, of course, the toxicities,” Armstrong said.

“The old paradigm was platinum chemotherapy and maintenance avelumab [Bavencio] followed by immunotherapy if [patients] didn’t get it, followed by enfortumab vedotin or erdafitinib [Balversa],” Tawagi summarized. “The new paradigm is frontline enfortumab vedotin/pembrolizumab, and second-line FGFR- or HER2-directed therapy with fam-trastuzumab deruxtecan-nxki [Enhetu], or platinum if you don’t have any of those options.”

Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD

In this video episode of OncLive On Air, Michael J. Pishvaian, MD, PhD, of the Johns Hopkins Kimmel Cancer Center in the National Capital Region, explained the changing role of biomarker-directed gastrointestinal oncology strategies and why early comprehensive testing is important for identifying molecular drivers of disease and treatment resistance mechanisms in the first-line setting and beyond.

“We are leaving a group of patients behind,” Pishvaian noted. “The data [indicate that we’re not giving optimal care to approximately] 50% of patients if we’re not looking for the biomarkers that may be present. One thing I often teach the fellows is there’s nothing clinical about these patients that tell us that they have a microsatellite instability–high tumor or an NTRK fusion–positive tumor. It’s only by testing that we’ll ever figure out who those patients are and can get them the right therapy.”

Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond

In this video episode of Breast Cancer Briefing, host Sara Nunnery, MD, MSCI, of Tennessee Oncology in Nashville, welcomed Annie Bond, a breast cancer survivor and patient advocate, to share her breast cancer diagnosis and treatment story.

“I do not want anyone else to have to have metastatic breast cancer ever again,” Bond said. “I just don’t want to see it. I want it to be curable. I want us to have a better quality of life [for patients]. But I also know that there is no way we can stop breast cancer deaths without education about metastatic breast cancer and without funding for metastatic breast cancer research. So, I will never shut up, is my plan.”

“We are seeing an increasing incidence in breast cancer in younger women, and it’s just so important to see women like you who are more visible about sharing your story, especially on social media and just getting the word out there that you really do need to advocate for yourself,” Nunnery said to Bond.

How Reimagined Research Endeavors Intersect With Dignified End-of-Life Care: With D. Ross Camidge, MD, PhD; and Charles D. Blanke, MD, FACP, FASCO

In this episode of How This Is Building Me, host D. Ross Camidge, MD, PhD, was joined by Charles D. Blanke, MD, FACP, FASCO, of the Oregon Health & Science University Knight Cancer Institute in Portland, to talk through Blanke’s career path, which has featured targeted cancer therapy research and advocating for safe, patient-centered medical aid in dying practices.

“I obviously felt terrible for the patient, that they would wind up at death’s door by the time they got to my clinic,” Blanke shared. “I realized there’s a gap there that absolutely had to be filled for the patient’s benefit.”

“There’s this amazing dichotomy in you where [you are] developing therapies for cancer and then developing therapies at the end of life,” Camidge said of Blanke.

FDA Approval Insights: Brexu-Cel for Relapsed/Refractory MCL: With Luhua (Michael) Wang, MD

In this video episode, Luhua (Michael) Wang, MD, of The University of Texas MD Anderson Cancer Center in Houston, spotlighted the significance of the full FDA approval of brexucabtagene autoleucel (Tecartus; brexu-cel) for the treatment of adult patients with relapsed/refractory mantle cell lymphoma (MCL).

“The FDA finally is convinced that [brexu-cel] is a good therapy that can deliver good efficacy with good overall survival, [and with] long term follow-up data, they decided to fully approve [brexu-cel for MCL],” Wang emphasized. “[However], the community doctors do not have the means to deal with CAR T-cell therapy–associated toxicities, since almost all the CAR T-cell therapies are infused at CAR T-cell centers. [CAR T-cell centers are] usually tertiary centers approved by all the authorities to carry out the infusion and deal with the toxicities.”

Answering Key Clinical Questions About Esophageal Cancer Care: With Peter Enzinger, MD

In this episode, Peter Enzinger, MD, of Dana-Farber Cancer Institute in Boston, Massachusetts, discussed staging and diagnostic challenges in newly diagnosed esophageal cancer, evolving treatment patterns, emerging targeted therapy strategies in esophageal and gastroesophageal cancers. He also discussed ongoing clinical research of interest.

“The main pitfall is that we often don’t know for certain if a patient is metastatic or not, and that often requires additional testing,” Enzinger stated. “And the testing does need to be completed, because if the patient has a good response, in retrospect, we won’t know if the patient was metastatic or not.”

Evolving ESR1 Mutation Testing Directions Complicate the Future of Metastatic Breast Cancer Management: With Pedram Razavi, MD, PhD; and Dara S. Ross, MD

In this episode, Pedram Razavi, MD, PhD, and Dara S. Ross, MD, both from Memorial Sloan Kettering Cancer Center in New York, New York, highlighted the evolution of ESR1 mutation–directed breast cancer management, and key points about the phase 3 SERENA-6 trial (NCT04964934), data from which are currently under FDA review for a regulatory decision regarding switching to camizestrant upon the emergence of an ESR1 mutation during treatment with an aromatase inhibitor and a CDK4/6 inhibitor ahead of radiographic disease progression in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

“This is exactly value-based oncology,” Razavi said of the SERENA-6 trial design. “This is an unusual [trial] design in solid tumors, but it is the right design. This is exactly what we have set ourselves up for over the past decade or more, setting the stage to get to the point that we do a true circulating tumor DNA [ctDNA]–adaptive clinical trial. This was done in a phase 3 double-blind, placebo-controlled randomized clinical trial, and it delivered on the on the prespecified outcome.”

“Dual analysis by tissue-based sequencing and ctDNA-based sequencing is so valuable to identify biomarkers for targeted therapy,” Ross explained. “As a molecular pathologist, it’s important for me to remind everyone that you need to understand the assays that are being performed, [as well as] the limitations and advantages of all those assays.”

TKIs Continue to Move Forward and Expand Their Potential in CML: With Michael J. Mauro, MD

In this episode, Michael J. Mauro, MD, of Memorial Sloan Kettering Cancer Center, spotlighted the variety of TKIs that are clinically available for the management of chronic myeloid leukemia.

“We’ve grown accustomed to counseling patients that they need to follow a certain schedule if they have to take a drug twice a day on an empty stomach to eliminate or minimize the effect of acid blockade, for example,” Mauro explained. “With [a newly approved dasatinib (Sprycel)] formulation, we can now introduce them in the beginning [of treatment].”

Emerging Targets, Second-Line Standards, and Molecular Subtyping Signal a New Era in SCLC Care: With Jacob Sands, MD

In this episode, Jacob Sands, MD, of Dana-Farber Cancer Institute, emphasized the evolving small cell lung cancer treatment paradigm, explaining progress made with immunotherapy and the persistent challenges associated with managing this aggressive disease.

“I have patients right now who are more than a year from when they were in pretty bad shape, [with poor ECOG performance] status in some cases,” according to Sands. “Some of these [patients had] extensive brain metastases and leptomeningeal disease who had previously been irradiated and were not eligible to get more radiation. In some cases, their oncologists told them there are no other treatment options and that hospice is the only option.”

How Cancer Caregiving Shifts Perspectives in Oncology Practice: With D. Ross Camidge, MD, PhD; and Karen L. Reckamp, MD

In this episode of How This Is Building Me, Camidge was joined by Karen L. Reckamp, MD, of Cedars Sinai in Los Angeles, California, to discuss Reckamp’s oncology career journey and how it has more recently intersected with her role as a caregiver for her husband, who has cancer.

“As a caregiver, your problems will never be big enough,” Reckamp reflected. “Where do you go with all that? I don’t have the insight yet. I guess I haven’t been through far enough to know a better insightful answer, but what is clear is that you cannot go into the relationship with all those issues.”

“It’s easy for people to see the burden in the cancer patient,” Camidge said. “They can see the cumulative adverse effects. They can see the diagnosis of the word cancer, but nobody can see the caregiver bent double under a more invisible load.”

Advances in Cervical Cancer: Prevention, Immunotherapy, and the Rise of Antibody-Drug Conjugates: With Ursula A. Matulonis, MD; and Meghan E. Shea, MD

In this episode of From Discovery to Delivery: Charting Progress in Gynecologic Oncology, host Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, sat down with Meghan E. Shea, MD, of Beth Israel Deaconess Medical Center in Boston, to explore the current cervical cancer treatment paradigm, emphasizing the need for expanded screening and vaccination protocols, as well as the evolution of antibody-drug conjugates (ADCs) and immunotherapy use across disease settings.

“One of the most challenging types of cervical cancer to manage is persistent or recurrent disease in the radiation field,” Shea stated. “Immunotherapy and ADCs have helped open that option up, because it wasn’t that long ago that we didn’t have standard chemotherapy that would do much for those patients.”

“I remember when we first started using pembrolizumab as a single agent in recurrent cervical cancer,” Matulonis reflected. “There was pretty incredible hope that these drugs would just kind of tear apart the cancer.”

In-House Molecular Testing in NSCLC Improves Turnaround Time, Tissue Stewardship, and Multidisciplinary Coordination: Featuring Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD

In this episode, Anthony Chi, MD; Monica Peravali, MD; and Archana Jadhav, MD, all faculty at the Mid-Atlantic Permanente Medical Group in Maryland, highlighted the advantages and clinical considerations for implementing in-house next-generation sequencing (NGS) for patients with non–small cell lung cancer.

“When you give the specimen out to an external laboratory, you do not have control of the tissue anymore,” Cho explained. “You do not know what happens when you send the specimen out, as opposed to when we were doing the internal testing and we knew how much tissue we were testing."

“We tend to check on NGS for all stages, because now we have data to support neoadjuvant chemotherapy and immunotherapy,” Peravali added. “We want to make sure there are no mutations for which immunotherapy is contraindicated.”

“Promptly reaching out to pathology and finding out if they have adequate tissue is a first step that we do,” Jadhav noted. “Make sure you get an adequate sample.”